Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Apyx MedicalFRA:BOV 72 Days Payable is 43.77 as of Jun. 2026, which is 34% below its 10-year median of 66.75. GuruFocus rates FRA:BOV with a GF Score™ of 72/100 and a GF Value™ of €1.87. The stock has 2 warning signs investors should review. Among 794 Medical Devices & Instruments companies, Apyx Medical ranks worse than 67.38% on this metric.
The historical rank and industry rank for Apyx Medical's Days Payable or its related term are showing as below:
FRA:BOV'
s Days Payable Range Over the Past 10 Years
Min: 47.89 Med: 66.75 Max: 177.65
Current: 47.89
During the past 13 years, Apyx Medical's highest Days Payable was 177.65. The lowest was 47.89. And the median was 66.75.
FRA:BOV's Days Payable is ranked worse than 67.38% of 794
companies
in the Medical Devices & Instruments industry
Industry Median: 68.615
vs FRA:BOV: 47.89
Apyx Medical's Days Payable
declined
from Jun. 2025 (56.92) to Jun. 2026 (43.77).
It may suggest that Apyx Medicalaccelerated paying its suppliers.
The historical data trend for Apyx Medical's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:BOV vs INGN, QSI, QTRX: Days Payable Comparison
For the Medical Devices subindustry, Apyx Medical's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apyx Medical Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Apyx Medical's Days Payable distribution charts can be found below:
* The bar in red indicates where Apyx Medical's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Apyx Medical's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apyx Medical (FRA:BOV) has a Days Payable of 43.77 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Apyx Medical and its competitors. This is 34% below median its historical median of 66.75. Over the past decade, Apyx Medical's Days Payable has ranged from 47.89 to 177.65. According to the industry distribution chart, Apyx Medical ranks #535 out of 794 companies in the Medical Devices & Instruments industry, placing it in the top 67.4%.
Is Apyx Medical's Days Payable too high?
Apyx Medical's current Days Payable of 43.77 is 34% below median its 10-year median of 66.75. Over the past 10 years, this metric has ranged from a low of 47.89 to a high of 177.65. The Medical Devices & Instruments industry median Days Payable is 68.62. Apyx Medical's value of 43.77 is 36.2% below this industry median. Based on the distribution chart, Apyx Medical ranks #535 out of 794 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Apyx Medical has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Apyx Medical's Days Payable compare to INGN and QSI?
According to the Medical Devices & Instruments industry distribution chart, Apyx Medical ranks #535 out of 794 companies for Days Payable. This places Apyx Medical in the lower half of its industry. The industry median Days Payable is 68.62. Apyx Medical's value of 43.77 is 36.2% below this benchmark. Historically, Apyx Medical's own Days Payable has ranged from 47.89 to 177.65 over the past decade. While the company's 10-year median is 66.75 vs. the industry median of 68.62, Apyx Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.62, based on 794 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apyx Medical's current Days Payable of 43.77 is 36.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Apyx Medical and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apyx Medical's current Days Payable is 43.77, which is 34% below median its own 10-year median of 66.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apyx Medical stock overvalued right now?
Apyx Medical (FRA:BOV) has a current Days Payable of 43.77. The stock's GF Value™ is €1.87, compared to a current price of €2.56 — trading 36.9% above its estimated fair value. The current Days Payable is 43.77, which is 34% below median its 10-year median of 66.75 and 36.2% below the Medical Devices & Instruments industry median of 68.62. Apyx Medical's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Apyx Medical (FRA:BOV), the current Days Payable is 43.77 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apyx Medical (FRA:BOV) Overvalued in 2026?
Based on GuruFocus' analysis, Apyx Medical stock appears to be overvalued.
The current stock price of €2.56 is trading 36.9% above its estimated GF Value™ of €1.87.
Key valuation signals for FRA:BOV:
Days Payable: 43.77 (34% below median its 10-year median of 66.75)
GF Value™: €1.87 vs. price of €2.56 (36.9% above fair value)
Industry Position: 36.2% below the Medical Devices & Instruments median (#535 of 794)
No single metric tells the full story. See the FRA:BOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Surgical Aesthetics and Original Equipment Manufacturing (OEM). Its Surgical Aesthetics segment derives the majority of its revenue.
72GF Score
Get the complete analysis for FRA:BOV
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BOV has been successfully added to your 
